- Home
- TARS vs ZGN Comparison
TARS vs ZGN Comparison
Compare TARS & ZGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | ZGN |
|---|---|---|
| Founded | 2016 | 1910 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TARS | ZGN |
|---|---|---|
| Price | $62.93 | $13.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $89.00 | $11.28 |
| AVG Volume (30 Days) | 628.4K | ★ 731.7K |
| Earning Date | 05-06-2026 | 03-20-2026 |
| Dividend Yield | N/A | ★ 1.22% |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $56.43 | $5.17 |
| Revenue Next Year | $30.19 | $7.89 |
| P/E Ratio | ★ N/A | $25.94 |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $38.51 | $7.61 |
| 52 Week High | $85.25 | $13.50 |
Technical Indicators
Market Signals| Indicator | TARS | ZGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.29 | 63.96 |
| Support Level | $60.38 | $9.89 |
| Resistance Level | $67.24 | $13.38 |
| Average True Range (ATR) | 3.60 | 0.44 |
| MACD | 0.28 | 0.02 |
| Stochastic Oscillator | 53.36 | 88.69 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.